Fortress Biotech (FBIO) Aktievy
Fortress Biotech, Inc, tillsammans med sina dotterbolag, bedriver verksamhet som ett biofarmaceutiskt företag i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
FBIO Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortress Biotech, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$2.74 |
| 52 veckors högsta | US$4.53 |
| 52 veckors lägsta | US$1.70 |
| Beta | 1.16 |
| 1 månads förändring | 17.60% |
| 3 månaders förändring | -22.60% |
| 1 års förändring | 53.93% |
| 3 års förändring | -66.73% |
| 5 års förändring | -95.47% |
| Förändring sedan börsintroduktionen | -98.34% |
Senaste nyheter och uppdateringar
Recent updates
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Summary Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO’s subsidiaries give it optionality across multiple subsidiaries, equity stakes, and royalty streams. FBIO’s Journey Medical assets give it its branded dermatology portfolio. The newly approved Emrosi provides near-term revenues. But more importantly, Zycubo (CUTX-101) for Menkes disease was FDA-approved in January 2026. This created a Rare Pediatric Disease PRV for FBIO. PRVs can be extremely valuable, and given FBIO’s microcap status, it could be a major upside catalyst if they sell it at a good price. Read the full article on Seeking AlphaFBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earningsInvestors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...Aktieägarnas avkastning
| FBIO | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 10.5% | 2.4% | 1.1% |
| 1Y | 53.9% | 34.6% | 28.7% |
Avkastning vs industri: FBIO översteg US Biotechs branschen som gav 34.6 % under det senaste året.
Avkastning vs Marknaden: FBIO översteg US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| FBIO volatility | |
|---|---|
| FBIO Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: FBIO har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: FBIO s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 78 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc. bedriver tillsammans med sina dotterbolag verksamhet som ett biofarmaceutiskt företag i USA och internationellt. Företaget erbjuder Emrosi, en minocyklinhydrokloridkapsel med förlängd frisättning för behandling av rosacea; Qbrexza, en medicinerad tyghandduk för behandling av axillär hyperhidros; Accutane, ett oralt isotretinoinläkemedel för behandling av svår återkommande nodulär akne; Amzeeq, ett minocyklin topikalt skum för behandling av lesioner av icke-nodulär måttlig till svår acne vulgaris; Zilxi, ett minocyklin topikalt skum för behandling av lesioner av rosacea; Exelderm, en svampdödande kräm för utvärtes bruk; Targadox, ett oralt doxycyklinläkemedel för behandling av svår akne; Luxamend, en vattenbaserad emulsion för behandling av ytliga sår, mindre skärsår eller skrapsår, hudsår, donatorställen, första och andra gradens brännskador samt strålningsdermatit; och UNLOXCYT, en antikropp som blockerar death-ligand 1 för behandling av metastaserande skivepitelcancer i huden. Företaget utvecklar också CUTX-101, en koppar histidinatinjektion, som är i FDA-godkännandefasen för behandling av Menkes sjukdom; IV Tramadol, en intravenös formulering, som är i NDA/BLA-ansökningsfasen för behandling av akut postoperativ smärta; Dotinurad, en urattransportörhämmare, som är i fas III för behandling av gikt och kroniska njursjukdomar; CAEL-101, en monoklonal antikropp som reagerar på fibriller i lätta kedjor, som befinner sig i fas III för behandling av amyloidos med lätta kedjor; och Triplex, ett universellt rekombinant modifierat vaccinia ankara virusvektorvaccin, som befinner sig i fas II för behandling av cytomegalovirus, anti-humant immunbristvirus, non-hodgkin lymfom och akut lymfatisk leukemi.
Fortress Biotech, Inc. Sammanfattning av grunderna
| FBIO grundläggande statistik | |
|---|---|
| Börsvärde | US$91.02m |
| Vinst(TTM) | US$119.20m |
| Intäkter(TTM) | US$66.16m |
Är FBIO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| FBIO resultaträkning (TTM) | |
|---|---|
| Intäkter | US$66.16m |
| Kostnad för intäkter | US$34.25m |
| Bruttovinst | US$31.91m |
| Övriga kostnader | -US$87.29m |
| Intäkter | US$119.20m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 3.59 |
| Bruttomarginal | 48.23% |
| Nettovinstmarginal | 180.16% |
| Skuld/egenkapitalförhållande | 19.5% |
Hur har FBIO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/25 04:23 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Fortress Biotech, Inc. bevakas av 13 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |